Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 9202

Next Previous
Drug Profile

CV 9202

Alternative Names: BI 13618409; BI 1361849; CV-9202

Latest Information Update: 21 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac; Ludwig Institute for Cancer Research
  • Developer Boehringer Ingelheim; Cancer Research Institute; CureVac; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 05 Apr 2024 Efficacy and adverse events data from a phase I/II trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 29 Oct 2021 Ludwig Institute for Cancer Research in collaboration with Boehringer Ingelheim and MedImmune complete the phase I/II trial in Non-small cell lung cancer in USA (NCT03164772)
  • 25 Sep 2020 CV 9202 is still in phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Intradermal) (NCT03164772)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top